NEOGEN — Re-Testing Key Breakout Zone | Rally Ready?Price is currently retracing/pulling back to retest the prior resistance-turned-support zone around ₹2,000 – ₹2,070. This retest presents a potential high-probability setup for bulls.
Breakout & Retest: Neogen Chemicals recently completed a strong breakout from a prolonged falling wedge/trendline consolidation, pushing up toward the major horizontal resistance zone near ₹2,390.
Battery Materials Capex Momentum: Neogen Ionic's greenfield facility (Pakhajan, Gujarat) is nearing completion for commercial-scale manufacturing of electrolytes (under exclusive tech licensing from Japan’s MUIS) and lithium electrolyte salts.
QIP Capital Raise & Strong Earnings: The company reported strong demand recovery in its core chemicals division and recently approved raising up to ₹600 Crore via a QIP to deleverage the balance sheet and fund its ongoing battery materials expansion.
Global Non-FEOC Tailwinds: Demand for non-China sourced lithium salts remains robust globally as battery/EV cell manufacturers secure supply chains for US/EU export compliance.
Look for bullish confirmation price action (hammer candle, strong engulfing bar, or daily volume spike) in the ₹2,000 – ₹2,075 area before going long.
Logterm
COHANCE: Deep Value Turnaround Play | Pharma StockThe stock made a major bottom around the ₹267–₹285 zone and bounced back quickly.
It broke above the key blue line at ₹391.60 / ₹394.60, which is now acting as solid support.
The price is consolidating right now under the ₹514.85 resistance. Once it closes above this on a weekly chart, the uptrend is fully confirmed.
Cohance Lifesciences Ltd. has corrected over 80% from its all-time high. The huge drop was caused by a bad FY26, where profit and margins fell due to heavy business spending and inventory issues. However, the price has already factored in the worst news and is showing strong signs of bottoming out.
Heavy spending on assets and advanced technology platforms is now building deep value for long-term growth. With a highly experienced new leadership team taking charge to streamline operations and diversify concentration risk, management expects the business to bottom out in early FY27, with volume-led growth returning in the second half of the year.



